Retail Banker International on MSN

Money laundering costs $5.5tn across the globe: Napier AI

Napier AI’s 2025/26 global AML Index, researched by Napier AI in partnership with Global Data, ranks 40 global markets based ...

Combination therapy could expand treatment options for AML patients and extend survival

Acute myeloid leukemia (AML), an aggressive and often fatal blood cancer, has long resisted a class of drugs called ...
American Banker

When mergers increase, AML compliance headaches surface

Time and again, seemingly successful bank mergers have been rocked by revelations of poor anti-money-laundering compliance. Assessing the AML risk of a potential merger partner is extremely tricky, ...
Technology Networks

Dual Drug Approach Targets Acute Myeloid Leukemia

By combining proteasome inhibitors with a second drug that disables one of two backup survival pathways, the team was able to ...
Fox 5 San Diego

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – – ...
Business Insider

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occur in approximately 30% of ...
Nature

Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL

To further explore the potential of synthetic triterpenoids as possible novel agents for the treatment of AML, we determined the effects of CDDO and CDDO-m on apoptosis induction in vitro, using ...

Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML

Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher dose levels of 80 mg and 120 mg TUS, ...
Nasdaq

Kura Oncology and Kyowa Kirin to Present Updated Data on Ziftomenib in Combination with 7+3 for AML at EHA2025 Congress

Kura Oncology and Kyowa Kirin announced that clinical data from the KOMET-007 trial, evaluating ziftomenib in combination with the standard chemotherapy regimen of cytarabine and daunorubicin (7+3) ...